Search Result

Isoforms Recommended:	PLK2

Results for "

PLK2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Polo-like Kinase (PLK) (26) Akt (1) Apoptosis (10) Autophagy (3) c-Myc (1) GSK-3 (1) Microtubule/Tubulin (1) Mitosis (2) Necroptosis (1) Reference Standards (2) Small Interfering RNA (siRNA) (3) VRK (1)
By Research Areas:	Cancer (23) Cardiovascular Disease (1) Inflammation/Immunology (1)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

Inhibitors & Agonists

Natural
Products

Recombinant Proteins

Oligonucleotides

Targets Recommended: Polo-like Kinase (PLK)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-12137

Volasertib Maximum Cited Publications 35 Publications Verification BI 6727	Polo-like Kinase (PLK) Apoptosis	Cancer
Volasertib (BI 6727) is an orally active, highly potent and ATP-competitive Polo-like kinase 1 (PLK1) inhibitor with an IC₅₀ of 0.87 nM. Volasertib inhibits PLK2 and PLK3 with IC₅₀s of 5 and 56 nM, respectively. Volasertib induces mitotic arrest and apoptosis. Volasertib, a dihydropteridinone derivative, shows marked antitumor activity in multiple cancer models ^[2].

HY-15160

TAK-960 2 Publications Verification	Polo-like Kinase (PLK)	Cancer
TAK-960 is an orally available, selective inhibitor of polo-like kinase 1 (PLK1), with an IC₅₀ of 0.8 nM. TAK-960 also shows inhibitory activities against PLK2 and PLK3, with IC₅₀s of 16.9 and 50.2 nM, respectively. TAK-960 inhibits proliferation of multiple cancer cell lines and exhibits significant efficacy against multiple tumor xenografts .

HY-100789

ON1231320 2 Publications Verification	Apoptosis Polo-like Kinase (PLK) Mitosis	Cancer
ON1231320 is a highly specific polo like kinase 2 (PLK2) inhibitor with an IC₅₀ of 0.31 μM. ON1231320 blocks tumor cell cycle progression in the G2/M phase in mitosis, causing apoptotic cell death. ON1231320, an arylsulfonyl pyrido-pyrimidinone, has antitumor activity ^[2].

HY-15161

Ro3280 4 Publications Verification	Polo-like Kinase (PLK)	Cancer
Ro3280 is a potent, highly selective inhibitor of *PLK1* with an IC₅₀ and a K_d of 3 nM and 0.09 nM, respectively, and nearly has no effect on PLK2 and PLK3.

HY-108597

TC-S 7005 4 Publications Verification	Polo-like Kinase (PLK)	Cardiovascular Disease Inflammation/Immunology
TC-S 7005 is a Polo-like kinases (Plks) inhibitor with IC₅₀s of 4 nM, 24 nM and 214 nM for Plk2, Plk3, and Plk1, respectively .

HY-15158

SBE13 Hydrochloride	Polo-like Kinase (PLK) Autophagy Apoptosis	Cancer
SBE13 Hydrochloride is a potent and selective *Plk1* inhibitor, with an IC₅₀ of 200 pM; SBE13 Hydrochloride poorly inhibits Plk2 (IC₅₀>66 μM) or Plk3 (IC₅₀=875 nM).

HY-12137A

Volasertib trihydrochloride Maximum Cited Publications 35 Publications Verification BI 6727 trihydrochloride	Polo-like Kinase (PLK) Apoptosis	Cancer
Volasertib (BI 6727) trihydrochloride is an orally active, highly potent and ATP-competitive Polo-like kinase 1 (PLK1) inhibitor with an IC₅₀ of 0.87 nM. Volasertib trihydrochloride inhibits PLK2 and PLK3 with IC₅₀s of 5 and 56 nM, respectively. Volasertib trihydrochloride induces mitotic arrest and apoptosis. Volasertib trihydrochloride, a dihydropteridinone derivative, shows marked antitumor activity in multiple cancer models ^[2].

HY-114302

CCB02 1 Publications Verification	Microtubule/Tubulin	Cancer
CCB02 is a selective CPAP-tubulin interaction inhibitor, binding to tubulin and competing for the CPAP binding site of β-tubulin, with an IC₅₀ of 689 nM, and shows potent anti-tumor activity. CCB02 shows no inhibition on the cell cycle- and centrosome-related kinases, or the phosphorylation status of Aurora A, Plk1, Plk2, CDK2, and CHK1 .

HY-N8692

Dihydrobaicalein	Polo-like Kinase (PLK) VRK	Cancer
Dihydrobaicalein is a *PLK1* Inhibitor with an IC₅₀ of 6.3 μM. Dihydrobaicalein also inhibits *VRK2* and *PLK2. Dihydrobaicalein is a natural product that can be isolated from Scutellaria scandens* .

HY-RS10715

Plk2 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA) Polo-like Kinase (PLK)	Others
Plk2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Plk2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Plk2 Mouse Pre-designed siRNA Set A Plk2 Mouse Pre-designed siRNA Set A

HY-RS10714

PLK2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA) Polo-like Kinase (PLK)	Others
PLK2 Human Pre-designed siRNA Set A contains three designed siRNAs for PLK2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PLK2 Human Pre-designed siRNA Set A PLK2 Human Pre-designed siRNA Set A

HY-RS10716

Plk2 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA) Polo-like Kinase (PLK)	Others
Plk2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Plk2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Plk2 Rat Pre-designed siRNA Set A Plk2 Rat Pre-designed siRNA Set A

HY-115589

YLT-11	Polo-like Kinase (PLK) Apoptosis	Cancer
YLT-11 is a potent, selective and orally active *PLK4* inhibitor with K_d values of >10000, 653, >10000, 5.2 nM for PLK1, PLK2, PLK3, PLK4, respectively. YLT-11 shows antiproliferative activity. YLT-11 induces Apoptosis and cell cycle arrest at G2/M phase. YLT-11 show anticancer activity .

HY-176734

CZL-S092	Polo-like Kinase (PLK)	Cancer
CZL-S092 is a *PLK4* inhibitor with an IC₅₀ value of 0.9 nM and excellent selectivity over other *PLK4* family members (PLK1, PLK2, and PLK3). CZL-S092 exhibits anti-neuroblastoma activity in vitro (IMR-32 cells, IC₅₀ = 1.143 μM). CZL-S092 inhibits cell migration and halts the cell cycle and induces apoptosis. CZL-S092 can be used in studies of various cancers including neuroblastoma cancer .

HY-180895

Y207–5465	Polo-like Kinase (PLK)	Cancer
Y207–5465 is a potent and highly selective *PLK2* inhibitor with an IC₅₀ value of 584.3 nM. Y207–5465 shows only limited anti-cancer activity in HT-29 and HCT-116 cells. Y207–5465 can be used in cancer research .

HY-15158A

SBE13	Polo-like Kinase (PLK) Autophagy	Cancer
SBE13 is a potent and selective *Plk1* inhibitor, with an IC₅₀ of 200 pM; SBE13 poorly inhibits Plk2 (IC₅₀>66 μM) or Plk3 (IC₅₀=875 nM).

HY-15160B

TAK-960 dihydrochloride 2 Publications Verification	Polo-like Kinase (PLK)	Cancer
TAK-960 dihydrochloride is an orally available, selective inhibitor of polo-like kinase 1 (PLK1), with an IC₅₀ of 0.8 nM. TAK-960 dihydrochloride also shows inhibitory activities against PLK2 and PLK3, with IC₅₀s of 16.9 and 50.2 nM, respectively. TAK-960 dihydrochloride inhibits proliferation of multiple cancer cell lines and exhibits significant efficacy against multiple tumor xenografts .

HY-15160A

TAK-960 hydrochloride	Polo-like Kinase (PLK)	Cancer
TAK-960 hydrochloride is an orally available, selective inhibitor of polo-like kinase 1 (PLK1), with an IC₅₀ of 0.8 nM. TAK-960 hydrochloride also shows inhibitory activities against PLK2 and PLK3, with IC₅₀s of 16.9 and 50.2 nM, respectively. TAK-960 hydrochloride inhibits proliferation of multiple cancer cell lines and exhibits significant efficacy against multiple tumor xenografts .

HY-172364

PLK1-IN-12	Polo-like Kinase (PLK)	Cancer
PLK1-IN-12 is a highly selective and orally active *PLK1* inhibitor with an IC₅₀ of 20 nM. PLK1-IN-12 shows more selective for PLK1 than PLK2 (IC₅₀: >10000 nM) and PLK3 (IC₅₀: 3953 nM). PLK1-IN-12 exhibits anticancer potency across a broad spectrum of cell lines. PLK1-IN-12 can be used in anti-leukemia research .

HY-12137R

Volasertib (Standard) BI 6727 (Standard)	Polo-like Kinase (PLK) Apoptosis Reference Standards	Cancer
Volasertib (Standard) is the analytical standard of Volasertib. This product is intended for research and analytical applications. Volasertib (BI 6727) is an orally active, highly potent and ATP-competitive Polo-like kinase 1 (PLK1) inhibitor with an IC50 of 0.87 nM. Volasertib inhibits PLK2 and PLK3 with IC50s of 5 and 56 nM, respectively. Volasertib induces mitotic arrest and apoptosis. Volasertib, a dihydropteridinone derivative, shows marked antitumor activity in multiple cancer models ^[2].

HY-173212

PLK1-IN-13	Polo-like Kinase (PLK) c-Myc Apoptosis	Cancer
PLK1-IN-13 is a selective and orally active *PLK1* inhibitor (IC₅₀: 0.27 nM). PLK1-IN-13 also inhibits PLK2 (IC₅₀: 12.72 nM) and PLK3 (IC₅₀: 4.12 nM). PLK1-IN-13 arrests cell at G2 phase, induces apoptosis and down-regulates the transcription of the proliferation-related oncogene c-MYC. PLK1-IN-13 inhibits tumor growth, and can be used for research of acute myeloid leukemia (AML) .

HY-15160C

TAK-960 monohydrochloride	Polo-like Kinase (PLK)	Cancer
TAK-960 monohydrochloride is an orally available, selective inhibitor of polo-like kinase 1 (PLK1), with an IC₅₀ of 0.8 nM. TAK-960 monohydrochloride also shows inhibitory activities against PLK2 and PLK3, with IC₅₀s of 16.9 and 50.2 nM, respectively. TAK-960 monohydrochloride inhibits proliferation of multiple cancer cell lines and exhibits significant efficacy against multiple tumor xenografts .

HY-123702

CAP-53194	Polo-like Kinase (PLK)	Cancer
CAP-53194 is a selective Plk1 inhibitor with potential anticancer activity. CAP-53194 was identified by a high-throughput virtual screening approach using molecular docking, showing 100-fold selectivity for Plk1 over Plk2-4 and other cell cycle kinases. CAP-53194 is able to effectively exploit subtle differences between the binding sites of Plk1 and other Ser/Thr kinases, thereby enhancing their inhibitory effects. CAP-53194 meets the Lipinski compound analog criteria and passes other ADMET filters, indicating good compound compatibility. CAP-53194 belongs to a new class of potential Plk1 inhibitors suitable for subsequent compound development and testing .

HY-180896

8012–3246	Polo-like Kinase (PLK) GSK-3	Cancer
8012-3246 is a selective *PLK2* inhibitor with an IC₅₀ of 774.5 nM. 8012-3246 suppresses GSK3β phosphorylation. 8012-3246 exhibits potent anticancer activity against colorectal cancer .

HY-181051

PLK1-IN-16	Polo-like Kinase (PLK) Apoptosis	Cancer
PLK1-IN-16 is a selective polo-like kinase 1 (PLK1) inhibitor with an IC₅₀ of 0.25 nM. PLK1-IN-16 exhibits lower inhibitory potency against *PLK2* and *PLK3, induces G2 phase cell cycle arrest, induces apoptosis, and exhibits antiproliferative activity against tumor cells. PLK1-IN-16 can be stable under simulated gastric acid environmental conditions, and acceptable CYP 450 inhibition. PLK*1-IN-16 can be used for the study of triple-negative breast cancer (TNBC), breast cancer, leukemia .

HY-100789R

ON1231320 (Standard)	Apoptosis Polo-like Kinase (PLK) Mitosis Reference Standards	Cancer
ON1231320 (Standard) is the analytical standard of ON1231320 (HY-100789). This product is intended for research and analytical applications. ON1231320 is a highly specific polo like kinase 2 (PLK2) inhibitor with an IC50 of 0.31 μM. ON1231320 blocks tumor cell cycle progression in the G2/M phase in mitosis, causing apoptotic cell death. ON1231320, an arylsulfonyl pyrido-pyrimidinone, has antitumor activity ^[2].

HY-W162436

MCC1019	Polo-like Kinase (PLK) Akt Apoptosis Necroptosis Autophagy	Cancer
MCC1019 is a selective PLK1 PBD inhibitor with an IC₅₀ of 16.4 μmol/L. MCC1019 inactivates the AKT signaling pathway in cancer cells, and induces Apoptosis, Necroptosis and Autophagy. MCC1019 exhibits anticancer activity against lung cancer and prostate cancer ^[2].

Dihydrobaicalein	Structural Classification Flavonoids Labiatae Flavonones Plants Medicago truncatula Gaertn. Source Classification	Polo-like Kinase (PLK) VRK
Dihydrobaicalein is a *PLK1* Inhibitor with an IC₅₀ of 6.3 μM. Dihydrobaicalein also inhibits *VRK2* and *PLK2. Dihydrobaicalein is a natural product that can be isolated from Scutellaria scandens* .

Recombinant Proteins Recommended:

PLK2

Species:	Human (2)
Tag:	His (1) Tag Free (1) Strep (1)
Source:	E. coli (2)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P705589

	PLK2 Protein, Human (His-Strep) Serine/threonine-protein kinase PLK2; Polo-like kinase 2 (PLK-2; hPLK2); SNK; Serum-inducible kinase	Human	E. coli

HY-P705860

	PLK2 Protein, Human (C83S, V87T, A119S, A216S, C259A, C291S, L335T, Active) Serine/threonine-protein kinase PLK2; Polo-like kinase 2 (PLK-2; hPLK2); SNK; Serum-inducible kinase	Human	E. coli

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Plk2 Mouse Pre-designed siRNA Set A		siRNAs Mouse Pre-designed siRNA Sets
Plk2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Plk2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

PLK2 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
PLK2 Human Pre-designed siRNA Set A contains three designed siRNAs for PLK2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Plk2 Rat Pre-designed siRNA Set A		siRNAs Rat Pre-designed siRNA Sets
Plk2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Plk2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks